XMD-17-51 (TFA)

• Description :

  XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases[1].

• UNSPSC :

  12352005

• Target :

  AMPK; Bcr-Abl; ERK; Mps1; Polo-like Kinase (PLK) ; Trk Receptor

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; MAPK/ERK Pathway; Neuronal Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research :

  Others

• Assay Protocol :

  https://www.medchemexpress.com/xmd-17-51-tfa.html

• Purity :

  99.46

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1N(C)C2=CN=C(NC3=CN(C4CCNCC4)N=C3)N=C2N(C)C5=CC=CC=C15.OC(C(F)(F)F)=O

• Molecular Formula :

  C23H25F3N8O3

• Molecular Weight :

  518.49

• References & Citations :

  [1]WO 2014145909 A2.|[2]Yang WQ, Zhao WJ, Zhu LL, et al. XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression. Front Pharmacol. 2021;12:603453.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2436579-93-8]